Drug utilization pattern and cost for the treatment of severe sepsis and septic shock in critically ill cancer patients

International Journal of Clinical Pharmacy

Volumn 35, Issue 6, 2013, Pages 1245-1250

  Nazer, Lama ^a   Al Shaer, Mohammad ^a   Hawari, Feras ^a  

^a KING HUSSEIN CANCER CENTER   (Jordan)

Author keywords

Cancer; Cost; Drug utilization; Jordan; Sepsis; Septic shock

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CARBAPENEM; CEFEPIME; CEPHALOSPORIN DERIVATIVE; COLISTIN; GRANULOCYTE COLONY STIMULATING FACTOR; HYPERTENSIVE FACTOR; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE; TEICOPLANIN; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTERIUM CULTURE; CANCER CENTER; CANCER PATIENT; CANCER SURVIVOR; COHORT ANALYSIS; CRITICALLY ILL PATIENT; DATA BASE; DISEASE SEVERITY; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HUMAN; INFECTION; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SEPTIC SHOCK; TEACHING HOSPITAL;

ADULT; AGED; APACHE; CANCER CARE FACILITIES; COHORT STUDIES; CRITICAL ILLNESS; DRUG COSTS; DRUG UTILIZATION; FEMALE; HEALTH CARE COSTS; HUMANS; INTENSIVE CARE UNITS; JORDAN; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; SEPSIS; SHOCK, SEPTIC; SURVIVORS;

EID: 84892771382     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-013-9860-2     Document Type: Article

References (12)

1. Danai PA, Moss M, Mannino DM, Martin GS. The epidemiology of sepsis in patients with malignancy. Chest. 2006;129:1432-40.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546-54.
3. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 2002;28(2):108-21.
4. Williams MD, Braun LA, Cooper LM, Johnston J, Weiss RV, Qualy RL, et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care. 2004;8(5):R291-8 Epub 2004 Jul
5. Sogayar AM, Machado FR, Rea-Neto A, Dornas A, Grion CM, Lobo SM, et al. A multicenter, prospective study to evaluate costs of septic patients in Brazilian intensive care units. Pharmacoecomics. 2008;26:425-34.
6. Moerer O, Schmid A, Hofmann M, Herklotz A, Reinhart K, Werdan K, et al. Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med. 2002;28:1440-6.
7. Weber RJ, Kane SL, Oriolo VA, Saul M, Skledar SJ, Dasta JF. Impact of intensive care unit (ICU) drug use of hospital costs: a descriptive analysis with recommendations for optimizing ICU pharmacotherapy. Crit Care Med. 2003;31(1):S17-24.
8. Hawari FI, Al Najjar TI, Zaru L, Al Fayoumee W, Salah SH, Mukhaimar MZ. The effect of implementing high-intensity intensive care unit staffing model on outcome of critically ill oncology patients. Critical Care Med. 2009;37:1967-71.
9. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Suriviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165-228.
10. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296-327.
11. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;51:427-31.
12. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia and adult cancer patients. Cancer. 2006 May 15;106(10):2258.